<DOC>
	<DOCNO>NCT01953458</DOCNO>
	<brief_summary>- The cohort integrate clinical , genetic , pharmacogenomics , environmental , biomarkers behavioral data large number patient leading equipment crossdisciplinary translational research hepatitis . - The cohort main support estimate relative effect treatment cost-effectiveness study management treatment option chronic HCV ( Hepatitis C Virus ) HBV ( Hepatitis B virus ) infection .</brief_summary>
	<brief_title>Therapeutic Option Hepatitis B C : French Cohort</brief_title>
	<detailed_description>General schedule study : - Prospective multicenter national study - Duration inclusions:3 year - Effective : 25000 patient - Duration follow-up : 7-8 year - Duration cohort : 10 year Population : Twenty-five thousand people include followed investigator site , 15000 hepatitis C 10000 hepatitis B , accord usual follow-up liver disease . We aim include 50 % patient naive HCV treatment inclusion . Also HBV `` cure '' patient could include ( less 10 % ) . Design study : - During recruitment visit , demographic , clinical , biological virological data collect . The patient move several assessment involve questionnaire , measurement blood sample . - Then minimum follow-up one medical visit per year . The follow-up ( clinical data biological collection ) drive event base protocol develop cohort . - There specific treatment cohort . The scientific project structure 4 scientific thematic ax : - Therapeutics : - To analyze long term effect therapy - To study predictor virological response fibrosis progression ( regression ) pharmacokinetic/pharmacodynamics either HCV HBV treatment - Virology : - To understand molecular mechanism antiviral treatment success failure - To provide treatment recommendation prevent resistance achieve sustain definitive control infection - Pathology physiopathology : - To identify new pathophysiological target responsible chronic hepatitis severity , prognosis , evolution . - To validate new therapeutic combination base pathophysiological research - Public Health : - To identify psychosocial behavioral correlate access care , progression liver disease burden chronic viral hepatitis B C. - To evaluate cost-effectiveness HBV HCV treatment quality life</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>HBVpositive patient Chronic hepatitis B define positive HBsAg ( surface antigen hepatitis B virus ) least 6 month Acute hepatitis B define recent appearance ( &lt; 6 month ) detectable HBs Ag , Chronic hepatitis B serological remission HbsAgnegative , HB DNAnegative , With without association acute chronic hepatitis D. HCVpositive patient Chronic hepatitis C define positivity antiHCV antibody least 6 month positive HCVRNA Acute hepatitis C define recent appearance HCV RNA ( less 6 month ) patient risk factor ( without positive antibody ) Patients cure hepatitis C define longterm eradication , either spontaneous , positive antiHCV antibody associate negative RNA two collection 6 month interval time ; either treatment define negative viremia 3 month end treatment . HIV coinfected patient eligible cohort . Socalled vulnerable population ( minor , people guardianship protection , private individual protection make legal administrative decision ) Treatment ongoing hepatitis C stop since less 3 month Patients end life Woman whose pregnancy know</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatitis B C</keyword>
	<keyword>ANRS HEPATHER French Cohort</keyword>
</DOC>